A Radiopharma Developer Takes a Full Building — and Onshores Manufacturing

➤ The Signal

Life-science demand is concentrating in purpose-built manufacturing, not generic wet lab — and a full-building, single-tenant commitment de-risks a newly delivered campus in one signature.

After two years of oversupply headlines, greater Boston’s life-science story is narrowing to a specific kind of space: GMP manufacturing and specialized production, not the speculative lab that flooded the market. AdvanCell needs radiopharmaceutical infrastructure, and that space does not sit empty for long.

For the landlord, a single credit tenant taking an entire building fills the last of a new phase and sets a mark for the campus. For the region, it is another reshored drug-manufacturing footprint — capacity that was previously more likely to land offshore.

The underwriting is a credit-and-fit-out question, not a market-vacancy question. When the tenant needs the exact building, the general market’s vacancy rate stops driving the deal.

➤ Implications

Watch the split inside life science: commodity lab stays soft, while purpose-built manufacturing and production leases at full-building scale to single credits. Basis and tenant-improvement recovery — not headline vacancy — decide these deals.